专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080254059A1 Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby 审中-公开
标题翻译：腺病毒血清型26载体，核酸和由此产生的病毒
公开(公告)号：US20080254059A1
公开(公告)日：2008-10-16
申请号：US11884086
申请日：2006-02-07
申请人： Andrew J. Bett , Danilo R. Casimiro , John W. Shiver , Emilio A. Emini , Michael Chastain , David C. Kaslow
发明人： Andrew J. Bett , Danilo R. Casimiro , John W. Shiver , Emilio A. Emini , Michael Chastain , David C. Kaslow
IPC分类号： A61K39/00 , C12N15/00 , C12N5/06 , C12N15/87 , A61P37/00 , C12N7/00 , A61K35/76 , A61K31/70
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/54 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N2710/10321 , C12N2710/10343 , C12N2740/16134 , C12N2740/16234 , C12N2740/16334
摘要： Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 26, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for delivery and expression of heterologous genes are provided.
摘要翻译：腺病毒血清型的自然向性不同。已经发现各种各样的腺病毒血清型在至少它们的衣壳蛋白（例如，五邻体和六邻体蛋白），负责细胞结合的蛋白质（例如纤维蛋白）和参与腺病毒复制的蛋白质中不同。血清型中的向性和衣壳蛋白的这种差异导致了许多研究工作，旨在通过修饰衣壳蛋白来重新定向腺病毒向性。本发明绕过这样的衣壳蛋白修饰的要求，因为它呈现血清型26的重组复制缺陷型腺病毒，罕见的腺病毒血清型，以及产生替代重组腺病毒的方法。另外，提供了使用重组腺病毒递送和表达异源基因的方法。

2. 发明授权

US06733993B2 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications 失效
标题翻译：增强的第一代腺病毒疫苗表达密码子优化的HIV1-gag，pol，nef和修饰
公开(公告)号：US06733993B2
公开(公告)日：2004-05-11
申请号：US09952060
申请日：2001-09-14
申请人： Emilio A. Emini , Rima Youil , Andrew J. Bett , Ling Chen , David C. Kaslow , John W. Shiver , Timothy J. Toner , Danilo R. Casimiro
发明人： Emilio A. Emini , Rima Youil , Andrew J. Bett , Ling Chen , David C. Kaslow , John W. Shiver , Timothy J. Toner , Danilo R. Casimiro
IPC分类号： C12P2106
CPC分类号： C12N7/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

3. 发明授权

US06787351B2 Adenovirus carrying gag gene HIV vaccine 失效
标题翻译：携带gag基因HIV疫苗的腺病毒
公开(公告)号：US06787351B2
公开(公告)日：2004-09-07
申请号：US09818443
申请日：2001-03-27
申请人： Ling Chen , John W. Shiver , Andrew J. Bett , Danilo R. Casimiro , Michael J. Caulfield , Michael A. Chastain , Emilio A. Emini
发明人： Ling Chen , John W. Shiver , Andrew J. Bett , Danilo R. Casimiro , Michael J. Caulfield , Michael A. Chastain , Emilio A. Emini
IPC分类号： C12N1574
CPC分类号： C12N15/86 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12Q1/703
摘要： An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.
摘要翻译：描述了携带密码子优化的gag基因以及异源启动子和转录终止子的腺病毒载体。当病毒疫苗单独使用或作为初始和加强方案的一部分也可用疫苗质粒时，可有效预防HIV感染。

4. 发明授权

US07598362B2 Hepatitis C virus vaccine 有权
标题翻译：丙型肝炎病毒疫苗
公开(公告)号：US07598362B2
公开(公告)日：2009-10-06
申请号：US10492178
申请日：2002-10-10
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
IPC分类号： C07H21/04 , C12N7/00
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译：本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。

5. 发明申请

US20090233992A1 HEPATITIS C VIRUS VACCINE 有权
公开(公告)号：US20090233992A1
公开(公告)日：2009-09-17
申请号：US12396747
申请日：2009-03-03
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloen
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloen
IPC分类号： A61K31/7088
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译：本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。

6. 发明授权

US08142794B2 Hepatitis C virus vaccine 有权
标题翻译：丙型肝炎病毒疫苗
公开(公告)号：US08142794B2
公开(公告)日：2012-03-27
申请号：US12396747
申请日：2009-03-03
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
IPC分类号： C12N7/00 , C07H21/04
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译：本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。

7. 发明授权

US06689761B1 Combination therapy for HIV infection 失效
标题翻译：联合治疗艾滋病毒感染
公开(公告)号：US06689761B1
公开(公告)日：2004-02-10
申请号：US08382113
申请日：1995-02-01
申请人： Jeffrey A. Chodakewitz , Emilio A. Emini
发明人： Jeffrey A. Chodakewitz , Emilio A. Emini
IPC分类号： A61K3170
CPC分类号： A61K31/70 , A61K31/495 , A61K2300/00
摘要： The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
摘要翻译： HIV蛋白酶抑制剂化合物J，3TC和任选的AZT，ddI或ddC的组合可用于抑制HIV蛋白酶，HIV逆转录酶的抑制，HIV的感染的预防或治疗以及治疗 AIDS，作为化合物，药学上可接受的盐，药物组合物成分，无论是否与其它抗病毒剂，免疫调节剂，抗生素或疫苗组合。还描述了治疗艾滋病的方法和预防或治疗HIV感染的方法。

8. 发明授权

US4761470A Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody 失效
标题翻译：能够引发单纯疱疹病毒中和抗体的免疫原性合成肽
公开(公告)号：US4761470A
公开(公告)日：1988-08-02
申请号：US036651
申请日：1987-04-10
申请人： Emilio A. Emini , Vivian M. Larson , Joshua S. Boger
发明人： Emilio A. Emini , Vivian M. Larson , Joshua S. Boger
IPC分类号： C07K14/035 , C07K16/08 , C07K7/08
CPC分类号： C07K16/087 , C07K14/005 , C12N2710/16622 , Y10S930/224
摘要： A synthetic peptide, containing the predicted amino acid residues 64 to 77 of the herpes simplex virus type 1 (HSV1) gB structural glycoprotein open reading frame, a synthetic subunit immunogen that stimulates an immune response against HSV1 and which, when prepared, and chemically-conjugated to a protein carrier molecule, and inoculated into test animals, gives rise to a specific anti-peptide IgG response, such that these anti-peptide antibodies react with a purified HSV-specific structural glycoprotein preparation and are capable of neutralizing the infectivity of HSV1.
摘要翻译：含有单纯疱疹病毒1型（HSV1）gB结构糖蛋白开放阅读框的预测氨基酸残基64至77的合成肽，刺激针对HSV1的免疫应答的合成亚单位免疫原，与蛋白质载体分子缀合并接种到测试动物中产生特异性抗肽IgG应答，使得这些抗肽抗体与纯化的HSV特异性结构糖蛋白制剂反应并能够中和HSV1的感染性。

9. 发明授权

US5606030A Coconjugates of OMPC, HIV related peptides and anionic moieties 失效
标题翻译： OMPC的结合物，HIV相关肽和阴离子部分
公开(公告)号：US5606030A
公开(公告)日：1997-02-25
申请号：US305862
申请日：1994-09-14
申请人： Emilio A. Emini , William J. Leanza , Stephen Marburg , Richard L. Tolman
发明人： Emilio A. Emini , William J. Leanza , Stephen Marburg , Richard L. Tolman
IPC分类号： A61K35/74 , A61K35/76 , A61K38/00 , A61K39/00 , A61K39/21 , A61P31/12 , A61P31/18 , C07K1/113 , C07K14/00 , C07K14/155 , C07K14/16 , C07K14/195 , C07K14/22 , C07K14/41 , C07K16/10 , C07K16/12 , C07K19/00 , C07K17/02 , A61K39/385
CPC分类号： C07K14/005 , C07K14/22 , C07K16/1063 , C07K16/1217 , A61K38/00 , A61K39/00 , C12N2740/16122
摘要： A novel coconjugate comprising an immunogenic protein or protein complex having a first set of covalent linkages to low molecular weight moieties, --a.sup.--, which have an anionic or polyanionic character at physiological pH, and a second set of covalent linkages to peptides comprising Human Immunodeficiency Virus (HIV) Principal Neutralizing Determinants (PNDs), or peptides immunologically equivalent therewith, is useful for inducing anti-peptide immune responses in mammals, for inducing HIV-neutralizing antibodies in mammals, for formulating vaccines to prevent HIV infection or disease, including the Acquired Immune Deficiency Syndrome (AIDS), or for treating humans afflicted with HIV infection or disease.
摘要翻译：包含具有与低分子量部分具有第一组共价键的免疫原性蛋白质或蛋白质复合物的新颖的缀合物， - 在生理pH下具有阴离子或聚阴离子特征，以及与包含人免疫缺陷的肽的第二组共价键病毒（HIV）主要中和决定因子（PND）或与其免疫学相似的肽可用于在哺乳动物中诱导抗肽免疫应答，用于在哺乳动物中诱导HIV-中和抗体，用于配制疫苗以预防HIV感染或疾病，包括获得性免疫缺陷综合征（AIDS）或用于治疗患有HIV感染或疾病的人。

10. 发明授权

US5521082A Novel process for purification of hepatitis a virions 失效
标题翻译：用于纯化肝炎病毒粒子的新方法
公开(公告)号：US5521082A
公开(公告)日：1996-05-28
申请号：US967920
申请日：1992-10-28
申请人： John A. Lewis , Marcy E. Armstrong , Emilio A. Emini
发明人： John A. Lewis , Marcy E. Armstrong , Emilio A. Emini
IPC分类号： C12N7/02 , A61K39/29 , A61P31/12 , C12N7/00 , C12N7/04 , C12N7/08
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/5254 , C12N2770/32434 , C12N2770/32451
摘要： New methods for purifying Hepatitis A virus (HAV) are to commercial scale-up and manufacture of specific HAV vaccines, including formalin-inactivated HAV and attenuated HAV.
摘要翻译：用于纯化甲型肝炎病毒（HAV）的新方法是商业化扩大和制造特定的HAV疫苗，包括福尔马林灭活的HAV和减毒的HAV。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式